title: Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results.
abstract: BACKGROUND
  Recently, a clinical classification system was described to determine whether symptoms and signs of patients presenting with a first episode suggestive of multiple sclerosis (MS) indicate the presence of monofocal or multifocal disease.
  
  
  OBJECTIVE
  To evaluate the value of this new classification system by comparing the results with those of simultaneously obtained magnetic resonance imaging (MRI) scans.
  
  
  METHODS
  The 487 patients, randomised in the BENEFIT study, were centrally assessed using the new system and classified as monofocal or multifocal, based on clinical information by two neurologists masked for the MRI results. MRI analyses were performed by expert readers masked for the clinical classification.
  
  
  RESULTS
  Patients classified as multifocal had more T2 hyperintense (median: 21 versus 15.5) and more T1 hypo-intense lesions (median: 2 versus 1) than those classified as monofocal. Patients classified at the local site as having evidence of a single clinical lesion, but reclassified centrally as having a clinical multifocal central nervous system presentation, had more T2 lesions than monofocal patients. In addition, patients with a multifocal presentation more often fulfilled the MRI criteria for dissemination in space, as incorporated in the International Panel (IP) diagnostic criteria for MS.
  
  
  CONCLUSIONS
  These data provide justification for the recently proposed clinical classification system to be used in patients who present with a first episode suggestive of MS, in that ;multifocal', based on symptoms and signs, is associated with more lesions on MRI.
authors.affiliation: Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands. jm.nielsen@vumc.nl
authors.forename: J M
authors.initials: JM
authors.lastname: Nielsen
authors.forename: B
authors.initials: B
authors.lastname: Moraal
authors.forename: C H
authors.initials: CH
authors.lastname: Polman
authors.forename: P
authors.initials: P
authors.lastname: Poppe
authors.forename: M
authors.initials: M
authors.lastname: de Vos
authors.forename: M S
authors.initials: MS
authors.lastname: Freedman
authors.forename: L
authors.initials: L
authors.lastname: Kappos
authors.forename: F
authors.initials: F
authors.lastname: Barkhof
authors.forename: L
authors.initials: L
authors.lastname: Bauer
authors.forename: C
authors.initials: C
authors.lastname: Pohl
authors.forename: R
authors.initials: R
authors.lastname: Sandbrink
authors.forename: H-P
authors.initials: HP
authors.lastname: Hartung
authors.forename: B M J
authors.initials: BM
authors.lastname: Uitdehaag
mesh_terms: D000328:Adult; D005260:Female; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000145:classification / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology*
chemical_list: D007372:Interferons